Bristol-Myers Squibb, the $20 billion (sales) pharmaceutical giant, has put itself up for sale, according to a news report from Reuters. Itself a product of the 1989 merger of Bristol-Myers and Squibb Corporation, the company is said to be examining a number of options, including a possible combination with GlaxoSmithKline.
Click here to read the Reuters report.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments